CAG regimen combined with infusion of allogenetic bone marrow mesenchymal stem cells for treatment of hypoplastic relapsed acute myelogenous leukemia:One case report

Shi-feng Lu,Hua Lu,Peng Liu,Wen-yi Shen,Ming Hong,Jian-fu Zhang,Hui Yang,Jian-yong Li

DOI: https://doi.org/10.3321/j.issn:1673-8225.2008.16.002

2008-01-01

Abstract:Aim: To analyze the practicability and safety of the infusion of expanded in vitro human bone marrow-derived mesenchymal stem cells (MSCs) for a refractory and relapsed acute myeloid leukemia (AML) with hypo-proliferative bone marrow after chemotherapy. Methods: A 53-year-old woman was admitted to the First Affiliated Hospital of Nanjing Medical University in January 2002 and diagnosed with acute myeloid leukemia type M0, according to the French-American-British (FAB) classification. Complete remission (CR) was achieved after two courses of standard AML induction chemotherapy, consisting of homoharringtonine, etoposide, and Ara-C (cytarabine). An additional course of intensive chemotherapy (mitoxantrone, intermediate-dose cytarabine, daunomycin, and pirarubicin) was carried out for four years. In January 2006, a bone marrow examination revealed a hypocellular marrow with 47.6% blast cells. In March 2006, although she received a TAE regimen (pirarubicin, cytarabine, and etoposide), she did not achieve CR. A hypocellular marrow and severe agranulocytosis was maintained for approximately six months. Since she had a HLA-identical sibling sister, the patient was again admitted to hospital in July 2006 for human leukocyte antigen-identical allogeneic stem cell transplantation. Informed consents were obtained from the patient and her family members and the protocol was approved by Hospital Ethics Committee. On August 23rd 2006, she received a CAG regimen which consisted of aclarubicin (10 mg/d for 8 days), Ara-C (15 mg/d, twice daily for 14 days), and granulocyte colony-stimulating factor (G-CSF, 300 μ g/d from August 23rd to September 25th). During the course of chemotherapy of CAG, the patient developed severe invasive fungal infection. The patient received anti-infection treatment and infusion of expanded in vitro allogeneic MSCs from her human leukocyte antigen-identical sibling sister on the second day of the CAG regimen. The patient received a total of 1.4 × 106 mesenchymal cells/kg body mass to promote marrow hematogenesis recovery. Results: Fifteen days after MSC infusion, neutrophil granulocytes (NG) rose above 0.5 × 109 L-1. One month after MSC infusion, white blood cells count was 5.5 × 109 L-1, NG was 4.64 × 109 L-1, haemoglobin levels were 94 g/L, and platelets were 25 × 109 L-1. Peripheral blood gradually recovered to normal levels. Bone marrow examination revealed 0.4% blast cells with tri-lineage engraftment, while flow cytometry examination detected no micro-residual disease (MRD). She achieved CR again and recovered from severe invasive fungal infection. In the follow-up for 6 months, the patient maintained status of CR without any evidence of leukemia relapse or graft-versus-host disease. Conclusion: It is suggested that the combination of CAG regimen based on G-CSF priming, followed by infusion of MSCs is a promising new approach for the therapy of refractory and relapsed acute myeloid leukemia with long-term agranulocytosis. However, safety and efficacy need further validation by clinical trials.